Arrowstreet Capital
IRLA

Arrowstreet Capital’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Arrowstreet Capital’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-297
Closed -$749K – 1472
2021
Q4 		$749K Buy
+297
New +$1.81M ﹤0.01% 1214

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arrowstreet Capital's IRLA Position: Q1 2022 in Review

Arrowstreet Capital sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2022, closing a stake of 297 shares — an estimated $749K sold.

Arrowstreet Capital first reported a position in IRLA in Q4 2021 and held it in 1 quarter. The position peaked at $749K in Q4 2021. 85 funds tracked by Wall St. Rank hold IRLA as of Q1 2022.

  • Arrowstreet Capital reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 297 IRulya Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $749K.
  • Arrowstreet Capital first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Arrowstreet Capital's IRulya Therapeutics Inc. Common Stock position peaked at $749K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2022.

Based on Arrowstreet Capital's 13F filing for Q1 2022, filed 13 May 2022.